01 10Faslodex
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 580
2019 Revenue in Millions : 892
Growth (%) : -35
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 431
2020 Revenue in Millions : 580
Growth (%) : -26
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 334
2021 Revenue in Millions : 431
Growth (%) : -23
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 297
2022 Revenue in Millions : 334
Growth (%) : -11
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 720
2014 Revenue in Millions : 704
Growth (%) : -2%
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 941
2016 Revenue in Millions : 830
Growth (%) : 13
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 5.70%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,028
2017 Revenue in Millions : 941
Growth (%) : 9%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 830
2015 Revenue in Millions : 704
Growth (%) : 18
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 892
2018 Revenue in Millions : 1,028
Growth (%) : -13
